ANGLE plc (AIM:AGL)

London flag London · Delayed Price · Currency is GBP · Price in GBX
7.50
+0.20 (2.67%)
Jun 27, 2025, 4:35 PM GMT+1
-45.45%
Market Cap 24.11M
Revenue (ttm) 2.86M
Net Income (ttm) -14.23M
Shares Out 321.53M
EPS (ttm) -0.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 438,519
Average Volume 1,125,831
Open 7.55
Previous Close 7.50
Day's Range 7.50 - 7.87
52-Week Range 6.50 - 17.45
Beta 0.08
RSI 46.27
Earnings Date Sep 5, 2025

About ANGLE

ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated downstream analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, ... [Read more]

Industry Medical - Diagnostics & Research
Sector Healthcare
Founded 1994
Employees 119
Stock Exchange London Stock Exchange AIM
Ticker Symbol AGL
Full Company Profile

Financial Performance

In 2024, ANGLE's revenue was 2.86 million, an increase of 30.92% compared to the previous year's 2.19 million. Losses were -14.23 million, -29.34% less than in 2023.

Financial Statements

News

Angle PLC - EACR 2025: Data Demonstrating DNA Dual Analysis

ANGLE presents new data at EACR 2025 DEMONSTRATING DNA DUAL ANALYSIS FOR COMPREHENSIVE LIQUID BIOPSY PROFILING Poster highlights ANGLE's combined CTC-DNA and ctDNA analysis revealing tumour heterogene...

10 days ago - Accesswire

Angle PLC - EACR 2025: Innovation in AR Expression Profiling

ANGLE presents new data at EACR 2025 Highlighting Innovation in Androgen Receptor EXPRESSION profiling Poster presentation highlights development of a novel CTC-based assay GUILDFORD, SURREY / ACCESS ...

10 days ago - Accesswire

ANGLE plc Announces Novel Discoveries Into the Biology of Cancer

PARSORTIX SYSTEM enableS novel DISCOVERIES into the biology of cancer Academic and translational research is the driving force behind the pipeline of next generation cancer therapeutics GUILDFORD, SUR...

17 days ago - Accesswire

Angle PLC Announces Posting of Annual Report and Notice of AGM

GUILDFORD, SURREY / ACCESS Newswire / June 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research...

18 days ago - Accesswire

Angle PLC Announces Board Changes

GUILDFORD, UNITED KINGDOM / ACCESS Newswire / June 6, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

21 days ago - Accesswire

Angle PLC Announces Preliminary Results

Commercialization building with large pharma contracts secured Further progress on next generation sequencing assays for DNA dual analysis of CTC-DNA and ctDNA GUILDFORD, UNITED KINGDOM / ACCESS Newsw...

4 weeks ago - Accesswire

Angle PLC Announces Notice of Results

Notice of Preliminary Results and Webcast GUILDFORD, SURREY / ACCESS Newswire / May 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumou...

5 weeks ago - Accesswire

Angle PLC Announces Results of Eisai Phase 2 pilot study

UPDATE ON ASTRAZENECA ASSAY DEVELOPMENT PROJECTS AND SUCCESSFUL COMPLETION OF EISAI CONTRACT Development of both the prostate cancer androgen receptor assay and the multi-cancer DDR micronuclei assay ...

3 months ago - Accesswire

Angle PLC Announces Issue of LTIP Options and Share Options

GUILDFORD, SURREY / ACCESS Newswire / March 21, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholde...

3 months ago - Accesswire

Angle PLC Announces Analysis of CTC-DNA and ctDNA using Illumina assay

NEW RESULTS FOR dual analysis of CTC-DNA and ctDNA using Illumina assay and sequencing platform Findings in lung cancer show that CTCs can provide additional biomarkers not found in ctDNA from single ...

5 months ago - Accesswire

Angle PLC Announces Parsortix Used in Research Paper from ETH Zurich

CLINICAL TRIAL POWERED BY PARSORTIX SYSTEM PROVIDES FIRST-IN-CLASS data FOR NOVEL APPROACH TO CANCER treatment Parsortix system used to identify patients with highly metastatic CTC clusters for target...

5 months ago - Accesswire

Angle PLC Announces Trading Update

Revenue for 2024 expected to be up 31% Lower cost base going into 2025 with a growing sales pipeline of opportunities GUILDFORD, SURREY / ACCESS Newswire / January 23, 2025 / ANGLE plc (AIM:AGL)(OTCQX...

5 months ago - Accesswire

iRobot’s founder is working on a new kind of home robot

Colin Angle, the former CEO of iRobot, is launching a home robot startup. | Photo by Suzanne Kreiter/The Boston Globe via Getty Images Colin Angle, the co-founder of iRobot and its CEO for three decad...

6 months ago - The Verge

iRobot co-founder’s new home robot startup hopes to raise $30M

Colin Angle, one of the co-founders of Roomba maker iRobot, is raising cash for a home robotics venture. A filing with the U.S. Securities and Exchange Commission reveals that Angle’s new company, Fam...

6 months ago - TechCrunch

Angle PLC Announces HER2 Presentation at SABCS

WEILL CORNELL MEDICINE PRESENTS HER2 PARSORTIX WORKFLOW AT SAN ANTONIO BREAST CANCER SYMPOSIUM Independent findings support ANGLE's HER2 assay development programme Potential for stratification of bre...

7 months ago - Accesswire

Angle PLC Announces Research on HER2 Assay Kit Showcased at AACR

RESULTS FROM WORK TO DEVELOP A PARSORTIX-BASED Her2 assay KIT SHOWCASED AT INTERNATIONAL LIQUID BIOPSY CONFERENCE Parsortix-based HER2 kit being developed to provide an optimised, easily implemented, ...

8 months ago - Accesswire

Angle PLC Announces Parsortix Based PD-L1 Assay Showcased at AACR

CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ANGL...

8 months ago - Accesswire

ANGLE presents two posters at EACR

PARSORTIX-BASED ASSAYS SHOWCASED AT THE EUROPEAN ASSOCIATION FOR CANCER RESEARCH LIQUID BIOPSIES CONFERENCE Two posters highlight the importance of epitope-independent CTC enrichment and molecular cha...

8 months ago - Accesswire

Angle PLC Announces Parsortix enriched CTC & ctDNA in NSCLC patients

ANGLE plc ("the Company") DNA ANALYSIS OF PARSORTIX-ENRICHED CTCS AND CTDNA PROVIDES COMPLEMENTARY INFORMATION IN NSCLC PATIENTS TREATED WITH ASTRAZENECA'S OSIMERTINIB The addition of CTC-DNA analysis...

8 months ago - Accesswire

Angle PLC Announces Publication Demonstrates CTC Profiling Potential

PUBLICATION DEMONSTRATES POTENTIAL FOR multi-marker CTC profiling IN EARLY PROSTATE CANCER Parsortix enriched CTCs detected at high rates in localised disease Multi-marker profiling of CTCs could supp...

9 months ago - Accesswire

ANGLE PLC (ANPCY) (Q2 2024) Earnings Call Transcript Highlights: Key Takeaways from the ...

ANGLE PLC (ANPCY) (Q2 2024) Earnings Call Transcript Highlights: Key Takeaways from the Half-Year Report

9 months ago - GuruFocus

Half Year 2024 Angle PLC Earnings Call Transcript

Half Year 2024 Angle PLC Earnings Call Transcript

9 months ago - GuruFocus

Angle Plc reports 1H results

Angle Plc (ANPCY) reports 1H revenue of £1M, with a reduced loss of 21% at £7.7 million.

9 months ago - Seeking Alpha

Angle PLC Announces 100th Publication Supporting Parsortix System Use

GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repair ANGLE plc (AIM:AGL)(OTCQX:A...

9 months ago - Accesswire

Angle PLC Announces Half-year Report

Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLY Three Large Pharma contracts secured each with substantial revenue potential Strategic decision pos...

9 months ago - Accesswire